NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis $298.32 +1.82 (+0.61%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$298.56 +0.24 (+0.08%) As of 06/9/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Medpace Stock (NASDAQ:MEDP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medpace alerts:Sign Up Key Stats Today's Range$295.15▼$300.7950-Day Range$277.23▼$313.7452-Week Range$250.05▼$459.77Volume262,534 shsAverage Volume359,342 shsMarket Capitalization$8.57 billionP/E Ratio23.62Dividend YieldN/APrice Target$349.30Consensus RatingHold Company OverviewMedpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.Read More… Medpace Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreMEDP MarketRank™: Medpace scored higher than 94% of companies evaluated by MarketBeat, and ranked 117th out of 1,886 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingMedpace has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on 3 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageMedpace has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medpace's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth11.15% Earnings GrowthEarnings for Medpace are expected to grow by 11.15% in the coming year, from $12.29 to $13.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 23.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 23.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.17.Price to Earnings Growth RatioMedpace has a PEG Ratio of 3.81. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 11.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Medpace's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.44% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Medpace has recently increased by 8.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.62 Percentage of Shares Shorted12.44% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Medpace has recently increased by 8.61%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment1.46 News SentimentMedpace has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Medpace this week, compared to 11 articles on an average week.Search InterestOnly 2 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows7 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $516,716.00 in company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medpace's insider trading history. Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address MEDP Stock News Headlines2 Profitable Stocks to Target This Week and 1 to Turn DownJune 5, 2025 | uk.finance.yahoo.comIs Medpace Stock Worth the Hype? Here's What Analysts Think.May 27, 2025 | fool.comTrump’s Secret WeaponThe Trump-Elon War Could Trigger an Economic Collapse - Here's Your Only Safe Exit This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump and Elon Musk isn't just political theater. It's a direct threat to the stability of markets, the dollar, and your life savings. When two of the most powerful men in America go to war, the economy loses.June 10, 2025 | American Alternative (Ad)William Blair Remains a Hold on Medpace Holdings (MEDP)May 21, 2025 | theglobeandmail.comMajor Update: Cornelius P. McCarthy III At Medpace Hldgs Exercises Options, Realizing $0May 21, 2025 | benzinga.comDani S Zander Decides To Exercise Options At Medpace Hldgs Worth $0May 21, 2025 | benzinga.comMEDP Q1 Earnings Call: Outperformance Driven by Revenue Upside, Cautious Outlook Amid Funding UncertaintyMay 11, 2025 | finance.yahoo.comCocktail bar to close inside $115M Madisonville development following three-year runMay 1, 2025 | bizjournals.comSee More Headlines MEDP Stock Analysis - Frequently Asked Questions How have MEDP shares performed this year? Medpace's stock was trading at $332.23 at the start of the year. Since then, MEDP shares have decreased by 10.2% and is now trading at $298.32. View the best growth stocks for 2025 here. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) issued its quarterly earnings results on Monday, April, 21st. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a trailing twelve-month return on equity of 51.48% and a net margin of 19.17%. Read the conference call transcript. When did Medpace IPO? Medpace (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's top institutional investors include Vanguard Group Inc. (8.81%), Invesco Ltd. (4.13%), Mawer Investment Management Ltd. (2.42%) and Bessemer Group Inc. (1.93%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Stephen P Ewald, Kevin M Brady, Fred B Davenport Jr, Ashley M Keating and Robert O Kraft. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), McKesson (MCK), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings4/21/2025Today6/10/2025Next Earnings (Estimated)7/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:MEDP CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,200Year FoundedN/APrice Target and Rating Average Stock Price Target$349.30 High Stock Price Target$432.00 Low Stock Price Target$300.00 Potential Upside/Downside+17.1%Consensus RatingHold Rating Score (0-4)2.23 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$13.10 Trailing P/E Ratio23.62 Forward P/E Ratio24.27 P/E Growth3.81Net Income$404.39 million Net Margins19.17% Pretax Margin22.57% Return on Equity51.48% Return on Assets20.47% Debt Debt-to-Equity RatioN/A Current Ratio0.93 Quick Ratio0.93 Sales & Book Value Annual Sales$2.16 billion Price / Sales3.98 Cash Flow$12.07 per share Price / Cash Flow24.72 Book Value$27.10 per share Price / Book11.01Miscellaneous Outstanding Shares28,742,000Free Float24,282,000Market Cap$8.57 billion OptionableOptionable Beta1.47 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:MEDP) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredTrump’s treachery This might just be the greatest time in America to be an energy company. Since taking office in 2025, Presi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medpace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.